信达生物(01801.HK)治疗甲状腺眼病药物获准中国上市

阿斯达克财经
14 Mar

信达生物(01801.HK) 公布,重组抗胰岛素样生长因子1受体抗体信必敏的新药上市申请,获中国国家药品监督管理局批准上市,用于治疗甲状腺眼病。

公告指,信必敏是中国首个、全球第二款获批的IGF-1R抗体药物,也是中国甲状腺眼病治疗领域七十年来的首款新药,将重塑甲状腺眼病的治疗标准。(js/da)(港股报价延迟最少十五分钟。沽空资料截至 2025-03-14 12:25。)

AASTOCKS新闻

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10